Natural killer (NK) cells are supposed to hunt cancer cells. The problem: solid tumors shield themselves behind a web of immunosuppressive signaling molecules and neutralize these cells. Researchers at McGill University's Rosalind and Morris Goodman Cancer Institute have now found a way to break this blockade with small molecules.
Why the Immune System Often Fails Against Cancer
Natural killer cells patrol the bloodstream and recognize abnormal cells by missing or altered surface features. Unlike T-cells, they require no prior sensitization. They kill efficiently in healthy tissue. In tumors, cancer cells secrete signaling molecules that essentially put NK cells to sleep. Particularly potent is Transforming Growth Factor Beta 1 (TGFβ-1), a molecule known for wound healing that systematically suppresses immunity in the tumor environment.
Several pharmaceutical companies have tried to directly block TGFβ-1. Results have been disappointing, partly because the molecule serves many physiological functions and blocking it triggered side effects in other organs.
The New Approach: Turning Off Two Proteins in Killer Cells
McGill's team, whose results appeared in EMBO Reports in April 2026, pursued a different strategy. Instead of blocking TGFβ-1 itself, researchers inhibited two proteins within NK cells: PTPN1 and PTPN2. These protein-tyrosine phosphatases are intracellular brakes on NK cell activity. When inhibited, NK cells respond more sensitively to activation signals and produce more interleukin-2, boosting their killing power.
Critically, the team used reversible small-molecule inhibitors, not permanent genetic changes. NK cells can return to their original state after treatment. This is a major practical advantage over approaches permanently altering cellular genetics.
Four Cancer Types, One Mechanism
The activated NK cells were tested against four cancers: acute myeloid leukemia, glioblastoma (an aggressive brain tumor), renal carcinoma, and triple-negative breast cancer, a particularly difficult-to-treat subtype. In all four models, treated NK cells showed significantly elevated killing rates. The team reports that activated NK cells also resisted the standard immunosuppressor TGFβ-1 that normally completely paralyzes them.
Triple-negative breast cancer deserves special mention: this subtype doesn't respond to hormone therapies and has limited access to checkpoint inhibitors. New therapeutic approaches are urgently needed here.
In Comparison: What Other Immunotherapies Achieve
NK cells as therapy have a structural advantage over other immunotherapy forms: they can be harvested from donor blood and produced in large quantities without customizing for individual patients. This fundamentally distinguishes them from CAR-T cells, which received first approvals in 2017. CAR-T requires extracting a patient's own cells, genetically reprogramming them, and re-infusing them. The process takes weeks and costs several hundred thousand dollars, severely limiting access.
Checkpoint inhibitors, in clinical use since 2014 blocking PD-1 or PD-L1, achieve impressive long-term remissions in some cancers. Their mechanism assumes T-cells are functional and numerous enough within the tumor. Glioblastomas and renal carcinomas are known to prevent this. Here, the NK cell route could offer a supplement or alternative.
The Path to Clinic: Acute Leukemia First
McGill's team has named acute myeloid leukemia (AML) as the first cancer for future clinical trials. This makes therapeutic sense: in AML, cancer cells circulate in the blood and are easily accessible to infused NK cells. Solid tumors like glioblastoma present a higher mechanistic hurdle because NK cells must first penetrate tumor tissue.
The typical path from preclinical data to market approval takes 10 to 15 years in oncology. If planned Phase I studies begin within the next two to three years and yield positive safety data, earliest patient access outside studies could come in the first half of the 2030s. For cancer patients diagnosed with AML today, this is no quick solution. But it is the kind of foundational mechanism research all future NK cell therapies will build upon.